H.J.A. Hunter - Concepedia

Author

H.J.A. Hunter

Manchester Academic Health Science Centre ORCID

Also Known As

Gregorio Carretero, H HUNTER, H Hunter, H. Hunter, H. J. A. Hunter, H.J.A. Hunter, Hamish Hunter, Hamish J A Hunter, Hamish J. A. Hunter, Hamish J.A Hunter

Publications

745

Citations

H-Index

Concepts

All Affiliations

Manchester Academic Health Science Centre NIHR Manchester Biomedical Research Centre Bispebjerg Hospital Ludwig-Maximilians-Universität München Salford Royal NHS Foundation Trust

About

H.J.A. Hunter is an author at Manchester Academic Health Science Centre specializing in medicine, dermatology, and clinical outcomes.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	273
2	Social Sciences	1	1	166
3	Neurology	1	1	166
4	Neuroscience	1	1	166
5	Pathology	1	1	12

H.J.A. Hunter

Publications

341

Citations

H-Index

Page 1

	Year	Citations
Persyn, a Member of the Synuclein Family, Has a Distinct Pattern of Expression in the Developing Nervous System Vladimir L. Buchman, H.J.A. Hunter, Luzia G. P. Piñón, Journal of Neuroscience Cellular NeurobiologySocial SciencesDeveloping Nervous SystemUnique FamilyExperimental Neuropathology	1998	166
Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study Kim S Thomas, Anthony D. Ormerod, Fiona E. Craig, Journal of the American Academy of Dermatology Pyoderma GangrenosumTopical DrugClinical DermatologyClinical OutcomesDermatology	2016	62
Diurnal and seasonal variation in psoriasis symptoms Felicity J. Ferguson, Georgia Lada, H.J.A. Hunter, Journal of the European Academy of Dermatology and Venereology MedicineClinical DermatologySeasonal VariationDermatologyPsoriatic Arthritis	2020	33
Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre Firas C. Kreeshan, Ali Al‐Janabi, Richard B. Warren, Dermatology and Therapy	2020	26
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS) Richard B. Warren, Lars E. French, Andrew Blauvelt, Journal of the American Academy of Dermatology	2023	26
Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial Jacob P. Thyssen, Thomas Werfel, S. Barbarot, Journal of Dermatological Treatment	2023	16
Bullous pyoderma gangrenosum in acute myeloid leukaemia Daniel H. Wiseman, H.J.A. Hunter, Michael Dennis European Journal Of Haematology Hematological MalignancySurgical PathologyHematologyHistopathologyPathology	2007	12

Page 1